This panel will discuss, among other things: (i) the goals of implementing solid corporate governance infrastructure including transparency, equity among shareholders, and maintaining the integrity and legitimacy of a cannabis company in particular; (ii) the importance of advising clients about best practices for effectively maintaining and enforcing corporate governance systems by, including, but not limited to, adhering to the often-overlooked federal guidelines from the United States Sentencing Commission; and (iii) the importance of implementing corporate governance controls and policies during a company’s infancy; and (iv) lessons learned from high-profile cannabis companies whose poor corporate governance practices had a damaging impact, including companies like Namaste Technologies.
Hear from the panel about what “also advise” means in practice, including what federal laws are considered “related,” how to determine if federal law “conflicts” with what your client seeks to do, and how to ensure you have adequately advised your client to comply with the new Rule 1.2 provision.
This panel will cover not only the law and current developments, but also offer practical advice for traveling, consuming, and securing privilege while practicing cannabis law.
This panel seeks to get to the bottom of the IFR and what it means for the hemp CBD industry currently and in the future. We may also touch on the intersection of USDA and FDA authority to regulate hemp-derived CBD products.
Join us for an update - from the comments that INCBA has submitted to the CDFA on behalf of the industry, to the most important aspects of the regulations, and what is necessary to make appellations of origin a functional tool for consumer education and choice in the cannabis industry.
This panel will address current and emerging challenges surrounding such methods and new products from the business, legal, and regulatory perspectives. Topics will include the vaping crisis, regulation of novel delivery systems, hardware inputs and related supply chain matters, various approaches to the regulation of edibles, hemp, and hemp-derived CBD, and what the future may hold.
This panel will discuss the most relevant issues within this area and the best practices applied by leading practitioners in this field. The panel will provide an overview of financing opportunities and methods, timing for investments and other financing vehicles, and positioning your clients for responsible growth.
Take a look at how to shore up those international supply chain needs, the potential of interstate commerce under state-implemented Memoranda of Understanding, and the future of supply chain consistency in a post-legalized world.
Join us for a discussion of the most important aspects of corporate governance, and how we can learn from some of the high profile failures in the industry.
This session will explore the science behind the various rules and regulations in different states and explore key aspects that lawyers and regulators should know.
We’ll cover where the power to regulate/enforce gets vested, and through which agency/agencies, how cannabis becomes legalized: whether through legislation, ballot measures, or litigation, and the COVID Impact: what an “essential” designation means for cannabis as a driver of international economic development.
This session will look at how an international supply chain for recreational cannabis products can be designed and how the enormous demand for products from legal markets can be satisfied. What conditions need to be created at the level of international law to make global trade possible? And what about import duties, safety standards and Intellectual Property?
With the 2018 Farm Bill well under our belts, and implementation of the USDA Rules well underway, let’s take a look at how the world is changing under the new regime. The sunset of the old administrative regimes left over from the 2014 Farm Bill and the rise of the 2018 Farm Bill regulations have created a new way to navigate the hemp industry. Join us to take a look at the terrain ahead.
Attendees will leave with an understanding of the best practices employed by lawyers and consultants in guiding businesses through these complicated applications, in particular how to assist one client in securing licenses in multiple states with varying qualification standards.
Many jurisdictions require applicants to engage in a competitive licensing process – and, as we all know, in a competitive process, there are winners and losers. Sometimes the winners don’t deserve to win, and sometimes the losers don’t deserve to lose. Take a look at how you can fight back when things don’t go your client’s way – from challenging the process to suing your jurisdiction, and everything in between.
Jeena Cho will cover resilience, work/life integration, and wellness in the workplace. Her area of expertise includes women’s issues, diversity, wellness, productivity, mindfulness, and meditation. Richard Carlton will be covering substance abuse and depression disorders. He will dive into the relation between practicing law and the mentality necessary to "succeed" at practicing law.
Panelists will discuss how cannabis use and substance abuse issues can interfere with an attorney’s competence obligations, and mandatory reporting requirements.
Of all white collar professionals in the United States, alcoholism and depression are most common among lawyers. And we serve an industry that makes an intoxicant more widely available than it has ever historically been. So, what does that mean for our own mental health and our own battles with substance abuse.
Join us for a discussion of patents, patent rights, limitations of patents, and alternatives for protection, from utility to Plant Patents and PVP. Additionally, the panel will delve into deposit requirements (availability to 3rd parties and timing of deposit), data- quality, scope (written description/enablement), and the dynamics for Plant Patent-Flexibility and data quality requirements, and patent enforcement.
Niall will discuss cannabis jurisdiction, legislation, regulation, Medical Cannabis Access Programme (MCAP, the Specified Controlled Drugs (Cannabis-Based Medical Products), indications, CBD - Novel Foods (Conflict of Laws), and adult use in the Republic of Ireland.
This panel seeks to address the pathways for federal cannabis reform in the 117th
Congress, considering legislative vehicles, political pragmatism, and actions of the
Administration.
In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.
The purpose of this webinar is to provide a clear overview of the current regulatory landscape in France on both medical cannabis and wellness hemp/CBD and to answer some frequently asked questions in order to provide some practical tips as to what can be done or not and what to expect in the near future.
Those already in the cannabis industry and those looking to get into it will get a chance to learn more about newest adult-use markets in the country, how they compare to one another, and what we can anticipate as these new opportunities take shape.
This one hour session will touch on the legal framework of recreational and medicinal cannabis in Switzerland and provide a high-level overview of the newest developments, the challenges, as well as the opportunities in Switzerland’s dynamic cannabis market.
As hemp policy continues to evolve, ensure you are staying at the forefront of regulatory developments to provide your clients with the best counsel for the 2021 production season.
With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
This webinar provides an overview of the appellate process. Attendees will become acquainted with the phases of an appeal as well as key concepts like error preservation, the record, amicus practice, standards of review, and more.
This CLE explores whether a mark owner has used its mark to sell improperly labeled soap or an illicit drug, the PTO has no mandate, and no convincing policy reason, to deny the owner the substantial benefits of registration.
This webinar will review the different types of internal documents which are needed for a business entity in the cannabis industry, and key considerations for drafting
Discover potential conflicts related to Federal agencies for marketers of Cannabis products, from limitations on intellectual property protection to agency enforcement action to litigation.
After becoming a cannabis lawyer, you need to ensure you are an ethical one. Learn from our panelists about the issues they confronted as soon as they entered cannabis practice, and what they never expected.
Most lawyers dream of having many clients seeking their services no matter how problematic. Our panelists debate how to manage conflicts of interest during competitive licensing and applications.
The recreational cannabis industry has emerged in Spain. We will explore the process to get cultivation licenses for medical cannabis producers, leading products in the market, the social impacts of cannabis clubs, and the realities of the hemp market.
This panel of experienced practitioners will provide insight and guidance in spotting and trouble shooting the issues at the early stages of the evaluation and negotiation of cannabis business transactions.
Social Equity: Social Equity and Justice for the Indigenous Community. This CLE will focus on social equity and social justice issues within the indigenous community. Speakers will discuss tribal sovereignty, federal and state recognized tribes and barriers to entry for indigenous tribes into the cannabis industry.
